title: A phase I trial of trimetrexate (NSC352122) on a daily x 5 schedule in patients with refractory adult leukemia.
abstract: Seven adult patients with refractory acute leukemia were administered trimetrexate (TMTX), a non-classical folate antagonist, in a phase I trial. TMTX was administered as an intravenous bolus for five consecutive days at doses of 9-12 mg/m2 based on marrow response. The maximum tolerated dose was 12 mg/m2. Hepatotoxicity was the dose-limiting toxicity. Initial dosage reductions in patients with liver disease and/or low protein concentrations may be necessary since TMTX is significantly protein bound and cleared primarily by hepatic metabolism. The recommended phase II dose on this dosing schedule is 9 mg/m2.
authors: University of Texas Health Science Center, San Antonio.
authors: G
authors: G
authors: Rodriguez
authors: T D
authors: TD
authors: Brown
authors: F M
authors: FM
authors: Balis
authors: J B
authors: JB
authors: Craig
authors: C A
authors: CA
authors: Denham
authors: J G
authors: JG
authors: Kuhn
authors: K
authors: K
authors: Havlin
authors: D D
authors: DD
authors: Von Hoff
mesh_terms: D000328:Adult; D002851:Chromatography, High Pressure Liquid; D004351:Drug Resistance; D005260:Female; D006207:Half-Life; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D016597:Trimetrexate / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D016597:Trimetrexate